LIVE WEBINAR: Monday, October 4, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

Identifying, Managing and Mitigating Therapy-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

A CME/MOC-Accredited Virtual Event

 

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Monday, October 4th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Richard R Furman, MD
Director, CLL Research Center
Weill Cornell Medicine
New York, New York

Lindsey Roeker, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Cardiologist
Daniel J Lenihan, MD
President, International Cardio-Oncology Society
Professor and Director, Cardio-Oncology Center of Excellence
Washington University in St Louis
St Louis, Missouri

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Abbvie Inc and AstraZeneca Pharmaceuticals LP.

Monday, October 4, 2021
5:00 PM – 6:00 PM Eastern Time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Monitoring and management algorithms for cardiac and other toxicities encountered by patients undergoing treatment with BTK inhibitors for CLL and MCL
  • Strategies to mitigate and manage tumor lysis syndrome and other AEs reported with venetoclax-based therapy in CLL and MCL
  • Tolerability observed with combined BTK/Bcl-2 inhibitor therapy in CLL and MCL clinical trials; implications for future practice
  • Role of multidisciplinary specialists (eg, cardio-oncologists) in the management of treatment-related AEs

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, cardiologists and other allied healthcare professionals involved in the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the frequency and severity of various therapy-related adverse events (AEs) commonly encountered by patients undergoing treatment with BTK and Bcl-2 inhibitors for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and enact effective monitoring processes and procedures for appropriate individuals.
  • Recall strategies commonly employed to identify, manage and mitigate AEs associated with these agents, and, when necessary, use this information to appropriately intervene in patients for whom toxicities are suspected or diagnosed.
  • Compare and contrast the side-effect and toxicity profiles of the various FDA-approved BTK and Bcl-2 inhibitors, and recall the patient- and disease-specific factors affecting the decision to commence treatment with one versus the others.
  • Appraise the role of multidisciplinary specialists, such as cardio-oncologists and rheumatologists, in the management of treatment-related AEs, and effectively collaborate with these clinicians to offer best-practice care for patients with CLL and MCL experiencing these toxicities.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr FurmanConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Sanofi Genzyme; Data and Safety Monitoring Board/Committee: Incyte Corporation; Speaking Engagements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd. Dr LenihanAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eidos Therapeutics, Ipsen Biopharmaceuticals Inc, Prothena; Consulting Agreements and Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc; Contracted Research: Myocardial Solutions Inc. Dr RoekerConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: Aptose Biosciences, Pfizer Inc; Ownership Interest: Abbott Laboratories.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Abbvie Inc and AstraZeneca Pharmaceuticals LP.